AstraZeneca stock pre-market at EUR 141.20: plus 0.23 percent
Published on 10/07/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock was at EUR 141.20 pre-market at 7:48 a.m. CEST on October 7, 2026, according to Lang & Schwarz. That was plus 0.23 percent versus the Lang & Schwarz prior close of EUR 140.88 on October 6, 2026.
Pre-market pricing
The Lang & Schwarz quote was EUR 141.20, with a bid of EUR 140.70 and an ask of EUR 141.70. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Summit investment announced
On September 28, 2026, AstraZeneca announced an agreement to invest $2 billion in newly issued equity in Summit Therapeutics. The company said the investment was intended to accelerate development of ivonescimab in combination with antibody-drug conjugates across tumor types. AstraZeneca also announced a clinical collaboration with Summit to evaluate sonesitatug vedotin with ivonescimab in gastrointestinal cancers.
Planned oncology collaboration
Under the announced terms, AstraZeneca said it would purchase approximately 109,000 preferred shares convertible into Summit common stock. Following completion, the investment was expected to give AstraZeneca rights equivalent to approximately 12.0 percent of Summit’s outstanding common stock, or approximately 10.6 percent on a fully diluted basis. AstraZeneca said closing of the preferred-stock investment was anticipated within one week of the announcement.
